I can provide an answer, and Mr. Matthews could add to it.
This is actually one of the reasons we have engaged in a discussion with Novavax to localize production. This does not concern only the existing vaccine. It's also in case we need an additional booster dose or new versions of the vaccine. The purpose of the ongoing work and other investments in Canadian options, such as Medicago, is to prepare us for potentially needing new versions of the vaccine.
This is certainly a priority for us in terms of biomanufacturing.